GlassScriptPhysician profile
Kimberly Barbolla
NPI 1437132081
$8,937.86
in general payments reported to CMS, 2019-2025
47 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $1,355 · 2021: $1,377 · 2022: $909 · 2023: $1,246 · 2024: $886 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,005.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $923.35 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $891.91 | 2021-2025 | |
| Lilly USA, LLC | $825.73 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $740.92 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $440.50 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $411.40 | 2019-2023 | |
| Allergan, INC. | $368.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.37 | 2019-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $267.53 | 2019-2022 | |
| Amarin Pharma, INC. | $243.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $237.30 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $233.18 | 2020-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.91 | 2019-2024 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $159.81 | 2019-2025 | Trelegy Ellipta, Arexvy |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Barbolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.